Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
Retrieved on:
Wednesday, May 17, 2023
DNA, Euronext Growth, Arm, ASH, Gene, CRS, Relapse, Neoplasm, Gene editing, Bone marrow, UCART123, Cyclophosphamide, FC, Cmax, Allotransplantation, DL2, Acute myeloid leukemia, MRD, CAR, AML, Patient, AUC, Annual general meeting, Alemtuzumab, Cytokine release syndrome, Cell, TGFB1, CR, FCA, American Society of Gene and Cell Therapy, Multi, Infrared spectroscopy correlation table, Cell engineering, PD-1, Safety, Tumor microenvironment, Society, Disease, Vaccine, Pharmaceutical industry, Medical imaging, Cellectis
Cytokine release syndrome (CRS) occurred in eight patients in the FC arm and nine patients in the FCA arm.
Key Points:
- Cytokine release syndrome (CRS) occurred in eight patients in the FC arm and nine patients in the FCA arm.
- The preclinical data demonstrate that multiplexed engineering does not compromise CAR T-cell function, which can even be enhanced and display improved anti-tumor activity.
- These preclinical data show that we can precisely select and combine an array of gene and cell engineering approaches to produce armored CAR T-cells with high efficiency rates.
- TALEN® and TALE-BE technologies can be integrated in the generation of CAR T-cells to provide high gene editing rates while preserving genomic safety.